Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey (Q34977411)

5 August 2017

title

Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey (English)

1 reference

5 August 2017

4

David W Bates

1 reference

5 August 2017

Rhema Vaithianathan

1

1 reference

5 August 2017

Peter M Hockey

series ordinal

2

1 reference

5 August 2017

Thomas J Moore

series ordinal

3

1 reference

5 August 2017

publication date

1 January 2009

1 reference

5 August 2017

1 reference

5 August 2017

volume

32

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

335-343

1 reference

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

5 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200932040-00007

Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study

21 January 2018

1 reference

12 December 2020

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

12 December 2020

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

12 December 2020

Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.

1 reference

12 December 2020

Community-based stroke incidence in a Scottish population: the Scottish Borders Stroke Study.

1 reference

12 December 2020

A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective

1 reference

12 December 2020

Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors

1 reference

12 December 2020

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

1 reference

12 December 2020

Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population

1 reference

12 December 2020

COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.

1 reference

12 December 2020

Acute coronary syndrome national statistics: challenges in definitions.

1 reference

12 December 2020

Non-steroidal anti-inflammatory drugs and cardiovascular risk

1 reference

12 December 2020

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

1 reference

12 December 2020

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis

1 reference

12 December 2020

Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction

1 reference

12 December 2020

Serious adverse drug events reported to the Food and Drug Administration, 1998-2005

1 reference

12 December 2020

Case fatality rates after admission to hospital with stroke: linked database study

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

10.2165/00002018-200932040-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1050983838

0 references

1 reference